Poseida Awarded $19.8 Million CIRM Grant to Support Clinical Trial of P-BCMA-101, a T Stem Cell Memory CAR-T Therapy for Multiple Myeloma

Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene therapy technologies into lifesaving cell therapies, today announced that the California Institute for Regenerative Medicine (CIRM) awarded a $19.8 million grant to support the clinical development of Poseida’s P-BCMA-101 product candidate. P-BCMA-101 is a chimeric antigen receptor T cell (CAR-T) immunotherapy currently in a Phase 1 clinical trial as a treatment for relapsed and refractory multiple myeloma.